Search filters

Filters
Clear All

Phase

  • 67
  • 68
  • 1
  • 82
  • 60
  • 13
  • 192
  • 559
  • 217
  • 9
  • 22
  • 531
  • 559
  • 3

Found 562 Barrett's Esophagus trials

A listing of Barrett's Esophagus medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

 High Velocity Nasal Insufflation (Hi-VNI) Use in Upper Airway Surgery
99 years or below
All genders
The goals of this study are to establish the efficacy of Hi-VNI in upper airway surgery from the anesthesiologists' and surgeons' perspectives, and to describe the ideal patient and the ideal pathology as well as suitable clinical scenarios when this oxygenation technique should be selected.
99 years or below
All genders
Phase 2
The main purpose of this study is to test the safety and efficacy (how well it works) of an experimental intervention called VY-AADC02 on the severity of PD. VY-AADC02 involves placing a gene in the brain that programs brain cells to produce an enzyme (protein) called AADC (aromatic amino acid …
99 years or below
All genders
The purpose of this study is to see if niraparib added to a standard treatment (abiraterone acetate and prednisone) will work better than abiraterone acetate and prednisone alone in treating men with metastatic prostate cancer with specific genetic changes. Eligible subjects will be men with metastatic prostate cancer.
99 years or below
All genders
The aim is to prospectively evaluate the efficacy and mechanism of benefit of HI-CRT vs. BIV CRT in patients with Right Bundle Brank Block (RBBB). Left Ventricular Ejection Fraction (LVEF) will be assess at 6 months following HIS CRT Vs. BIV CRT implant in Heart Failure patients with RBBB.
 A  Study of Osimertinib with or without Platinum Plus Pemetrexed Chemotherapy  as First-line Treatment in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation- Positive  Locally Advanced or Metastatic Non-small Cell Lung Cancer
18 years - 99 years
All genders
Phase 3
Interventional
The purpose of this study is to try to find out if an experimental combination of an oral medication called osimertinib when used in combination with chemotherapy is more effective than giving osimertinib alone for the treatment of non-small cell lung cancer (NSCLC). Eligible subjects will be adult subjects with …
 A Umbrella Study with Rolling Arms of Investigational Agents with Pembrolizumab in Combination with Chemotherapy in Treatment-Naive Patients with Advanced Non-small Cell Lung Cancer (NSCLC)
18 years - 99 years
All genders
Phase 2
This is a substudy of an umbrella study (MK-3475-U1). Subjects will be enrolled to the screening protocol and then subsequently enrolled to one of the substudies. This substudy examines investigational agents (MK-7684, MK-5890, MK-4830) in combination with pembrolizumab plus standard chemotherapy in treatment-naïve participants with advanced NSCLC.
 Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease (DRAMMATIC Study)
17 years - 75 years
All genders
Interventional
This study will examine whether adding the drug daratumumab/rHuPH20 to the usual maintenance treatment with lenalidomide after stem cell transplant help multiple myeloma patients survive longer. For patients who do not have minimum residual disease [MRD-negative], this study is also trying to determine if maintenance therapy should be stopped after …
18 years - 99 years
All genders
Interventional
The purpose of this study is to see if patients taking the study drug abelacimab have fewer bleeding events compared to those taking apixaban. Participation will last for about 8 months (6 months of treatment and 2 months of follow up). Participants may be paid up to a total of …
18 years - 99 years
All genders
Phase 3
Interventional
This research study is being done to see if patients taking the study drug abelacimab have fewer bleeding events compared to those taking dalteparin. Your participation will last for about 8 months (6 months of treatment and 2 months of follow up). Participants may be paid up to a total …
99 years or below
All genders
This protocol is an 18-month, multicenter, randomized, double-blind, placebo-controlled, phase 2 study comparing 1400 mg of donanemab versus placebo over 76 weeks in approximately 500 patients with early symptomatic AD. Study duration including screening and post treatment is up to 133 weeks. Study drug will be prepared and stored at …
171 - 180 of 562